Table 1 Baseline demographic data and clinical assessment of patients with depression in each group

Sex

Male (n, %)

6 (13.33)

27(60)

12(26.67)

0.849

Female (n, %)

17 (15.69)

60(55.05)

32(29.36)

Age

40.22 ± 14.65

41.85 ± 14.23

48.20 ± 9.18

0.016

BMI

22.19 ± 2.54

21.31 ± 2.97

22.10 ± 3.09

0.232

First episode/Relapse

First episode (n, %)

12 (13.79)

46 (52.88)

29 (33.3)

0.329

Relapse (n, %)

11 (16.42)

41 (61.19)

15 (22.39)

Antidepressant use (mg)

Fluoxetine

35.86 ± 7.24 (n = 2)

33.38 ± 12.16 (n = 6)

32.64 ± 11.42 (n = 3)

0.864

Paroxetine

28.94 ± 16.44 (n = 3)

31.72 ± 18.57 (n = 10)

29.62 ± 16.28 (n = 5)

Sertraline

164.32 ± 26.16 (n = 5)

152.84 ± 38.81 (n = 16)

143.72 ± 32.42 (n = 8)

Citalopram

35.12 ± 11.04 (n = 2)

35.62 ± 13.44 (n = 6)

34.87 ± 14.36 (n = 4)

Escitalopram

13.72 ± 4.47 (n = 3)

12.64 ± 3.32 (n = 14)

13.16 ± 5.44 (n = 6)

Agomelatine

36.22 ± 11.42 (n = 8)

32.36 ± 9.47 (n = 35)

33.34 ± 6.28 (n = 18)

HAMD_− 17

21.61 ± 8.16

23.02 ± 5.66

22.07 ± 3.92

0.466

HAMA

19.61 ± 9.44

21.16 ± 9.36

21.30 ± 5.09

0.595

MEQ

37.96 ± 2.87

50.02 ± 4.51

64.91 ± 3.85

< 0.0001

PSQI

14.91 ± 2.21

14.23 ± 3.54

14.55 ± 3.59

0.666

SHAPS

44.87 ± 4.35

46.64 ± 6.92

43.57 ± 2.19

0.012

MFI-20

81.82 ± 8.41

75.47 ± 12.50

85.34 ± 10.13

< 0.0001